No Data
Earnings Preview: KPTI to Report Financial Results Pre-market on May 12
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Why Levi Strauss Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
RBC Lowers Price Target on Karyopharm Therapeutics to $43 From $45, Keeps Outperform Rating
Piper Sandler Initiates Karyopharm Therapeutics(KPTI.US) With Buy Rating, Announces Target Price $15
ColdJoke : HK 6996. That revenue mainly goes to Antengene. We really got sucked badly and going to delist![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
.